Constarium
← Search

Excel · study · 2026

Degradation of AGO2 by TRIM25 drives cancer progression and chemotherapy resistance

Listed in NCBI GEO

AGO2, as a key member of the RISC complex, is underexpressed in a variety of tumor cells.

Description

It is shown that the E3 ligase TRIM25 is highly expressed in a variety of tumor cells and mediates the degradation of the ubiquitin-proteasome pathway of AGO2. This effect of TRIM25 on AGO2 promotes tumor progression and resistance of tumor cells to chemotherapeutic agents.

The specific mechanism is that TRIM25 regulates the level of miR-148b-5p in cells through AGO2, and then regulates the downstream ABCC1. Based on the above results, targeting miR-148b-5p provides a new strategy for the treatment of tumors.

Links

Topics

From keywords
Life Sciences
Inferred from text
Cancer 75%
Provenance · 1 source records, 9 field assertions
SourceKeyLast seenRaw
NCBI GEOGSE29030812 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[disease].local:disease:cancerenrichment · NCBI GEOkeyword-concept-rules@1.0.0title+description (75%)
concepts[field].local:field:life-sciencesmapping · NCBI GEOconnector:ncbi_geo@1.0.0
concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[method].geo_series_type:non-coding-rna-profiling-by-high-throughput-sequencingsource · NCBI GEOconnector:ncbi_geo@1.0.0/gdstype
concepts[organism].NCBITaxon:9606source · NCBI GEOconnector:ncbi_geo@1.0.0/taxon
descriptionsource · NCBI GEOconnector:ncbi_geo@1.0.0/summary
publication_datesource · NCBI GEOconnector:ncbi_geo@1.0.0
titlesource · NCBI GEOconnector:ncbi_geo@1.0.0/title